{"id":401948,"date":"2020-12-17T09:03:43","date_gmt":"2020-12-17T14:03:43","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401948"},"modified":"2020-12-17T09:03:43","modified_gmt":"2020-12-17T14:03:43","slug":"watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/","title":{"rendered":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\nWaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology\n<\/p>\n<p class=\"bwalignc\"><b><i>Highlights That Holders of More Than 50% of Ziopharm\u2019s Outstanding Shares Consented to Adding Each of WaterMill\u2019s Director Candidates<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>Thanks Shareholders for Significant Support and Reaffirms Commitment to Always Doing What is Best for Ziopharm<\/i><\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nWaterMill Asset Management Corp. (together with its affiliates, \u201cWaterMill\u201d or \u201cwe\u201d), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today announced that it received the requisite number of written consents to add all three of its director candidates \u2013 Robert Postma, Jaime Vieser and Holger Weis \u2013 to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Although each member of WaterMill\u2019s slate received support from holders of more than 50% of Ziopharm\u2019s outstanding shares, only Messrs. Vieser and Weis are able to join as directors due to the Company\u2019s Board currently being capped at eight members. WaterMill also received the requisite number of consents to remove Scott Tariff from the Board.\n<\/p>\n<p>\nRobert Postma, principal and founder of WaterMill, commented:\n<\/p>\n<p>\n\u201cWe are pleased that Jaime and Holger have joined Ziopharm\u2019s Board at this critical point in time. Jaime\u2019s capital allocation acumen, ownership perspectives and turnaround experience will be tremendous assets in the boardroom. Holger\u2019s c-level background in the life sciences sector, commercial intensity and finance expertise will also be extremely helpful in the pivotal months to come. They are fully committed to putting this contest behind them and immediately helping the Board chart the right path forward. Now that nearly 40% of the Board has been refreshed in recent weeks, Ziopharm should be well-positioned to begin enhancing its corporate governance and prioritizing strategic initiatives that are most likely to create meaningful near-term value for shareholders, providers and patients.\u201d\n<\/p>\n<p>\nMr. Postma concluded:\n<\/p>\n<p>\n\u201cWaterMill also wants to take this opportunity to thank its fellow shareholders for their incredibly thoughtful engagement throughout this process. While we anticipate that many supportive shareholders will be disappointed that our full slate is not joining the Board at this time, WaterMill is constructively engaging with Ziopharm to try to ensure that the message sent by a critical mass of investors is respected. WaterMill remains committed to always doing what is best for Ziopharm.\u201d\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201217005577\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201217005577\/en\/<\/a><\/span><\/p>\n<p>\nFor Investors:\n<\/p>\n<p>\nSaratoga Proxy Consulting<br \/>\n<br \/>John Ferguson \/ Joe Mills, 212-257-1311<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jferguson@saratogaproxy.com\">jferguson@saratogaproxy.com<\/a> \/ <a rel=\"nofollow\" href=\"mailto:jmills@saratogaproxy.com\">jmills@saratogaproxy.com<\/a><\/p>\n<p>\nFor Media:\n<\/p>\n<p>\nProfile<br \/>\n<br \/>Greg Marose \/ Charlotte Kiaie, 347-343-2999<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gmarose@profileadvisors.com\">gmarose@profileadvisors.com<\/a> \/ <a rel=\"nofollow\" href=\"mailto:ckiaie@profileadvisors.com\">ckiaie@profileadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Other Professional Services Professional Services Finance<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology Highlights That Holders of More Than 50% of Ziopharm\u2019s Outstanding Shares Consented to Adding Each of WaterMill\u2019s Director Candidates Thanks Shareholders for Significant Support and Reaffirms Commitment to Always Doing What is Best for Ziopharm NEW YORK&#8211;(BUSINESS WIRE)&#8211; WaterMill Asset Management Corp. (together with its affiliates, \u201cWaterMill\u201d or \u201cwe\u201d), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today announced that it received the requisite number of written consents to add all three of its director candidates \u2013 Robert Postma, Jaime Vieser and Holger Weis \u2013 to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Although each member of WaterMill\u2019s slate received support from &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401948","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology Highlights That Holders of More Than 50% of Ziopharm\u2019s Outstanding Shares Consented to Adding Each of WaterMill\u2019s Director Candidates Thanks Shareholders for Significant Support and Reaffirms Commitment to Always Doing What is Best for Ziopharm NEW YORK&#8211;(BUSINESS WIRE)&#8211; WaterMill Asset Management Corp. (together with its affiliates, \u201cWaterMill\u201d or \u201cwe\u201d), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today announced that it received the requisite number of written consents to add all three of its director candidates \u2013 Robert Postma, Jaime Vieser and Holger Weis \u2013 to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Although each member of WaterMill\u2019s slate received support from &hellip; Continue reading &quot;WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T14:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology\",\"datePublished\":\"2020-12-17T14:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/\"},\"wordCount\":448,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/\",\"name\":\"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-17T14:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/","og_locale":"en_US","og_type":"article","og_title":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk","og_description":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology Highlights That Holders of More Than 50% of Ziopharm\u2019s Outstanding Shares Consented to Adding Each of WaterMill\u2019s Director Candidates Thanks Shareholders for Significant Support and Reaffirms Commitment to Always Doing What is Best for Ziopharm NEW YORK&#8211;(BUSINESS WIRE)&#8211; WaterMill Asset Management Corp. (together with its affiliates, \u201cWaterMill\u201d or \u201cwe\u201d), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today announced that it received the requisite number of written consents to add all three of its director candidates \u2013 Robert Postma, Jaime Vieser and Holger Weis \u2013 to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Although each member of WaterMill\u2019s slate received support from &hellip; Continue reading \"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T14:03:43+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology","datePublished":"2020-12-17T14:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/"},"wordCount":448,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/","name":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-17T14:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005577r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/watermill-asset-management-issues-statement-regarding-consent-solicitation-at-ziopharm-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401948"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401948\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}